NEW YORK (GenomeWeb News) – Following Thermo Fisher Scientific's announcement today that it is buying One Lambda for $925 million, ratings agency Moody's Investors Service downgraded the company's senior unsecured rating and all rated senior unsecured notes.

Thermo Fisher's unsecured senior rating and notes were downgraded one notch to Baa1 from A3. Moody's affirmed the Prime-2 rating on Thermo Fisher's commercial paper program and said that the rating outlook is stable.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.